More than 6 million people in the U.S. are estimated to be living with Alzheimer’s disease (AD), and that number is expected to double by 2050. With a scarcity of Alzheimer’s specialists across the country, diagnosis and care commonly fall to primary care physicians (PCPs), who might lack the training and expertise required to accurately diagnose and effectively manage AD. To update PCPs on the latest advances in AD diagnosis and treatment, Rockpointe and the Potomac Center for Medical Education offer a free CME/AAFP, ABIM MOC activity in a live webinar format.
Too often early signs and symptoms of AD are missed or not given appropriate attention, delaying specialty referrals until later in the course of disease. Alzheimer’s is difficult to diagnose, but approval of the first blood test for AD in 2020 and the first disease-modifying therapy (DMT), aducanumab, in 2021 should begin to provide the armamentarium that has been missing from AD management since the disease was first characterized. Given that 85% of initial AD diagnoses are made by non-specialists yet almost 40% of PCPs aren’t comfortable making the diagnosis, it is vital that PCPs receive education to help them stay abreast of these recent developments, integrate them into practice where appropriate and in an evidence-based manner, and be aware of emerging developments in AD diagnosis and treatment.
A New Dawn in Alzheimer’s Disease Management: Recent Advances in Diagnosis and Treatment is a series of hour-long online continuing medical education courses that will provide the latest AD clinical developments in a manner that is most relevant to the primary care setting and will provide access to AD resources and experts to help prepare PCPs for the potential sea change in AD management. Participants will learn about detection of mild cognitive impairment and decline early in the course of disease, as well as current and emerging therapies. This educational activity is intended for primary care physicians and other clinicians who manage patients with AD and other dementias.
Dates and times
Tuesday, April 19, 2022
6:30 – 7:30 PM PT (9:30 – 10:30 PM ET / 8:30 – 9:30 PM CT)
Thursday, May 26, 2022
7:00 – 8:00 PM CT (8:00 – 9:00 PM ET / 5:00 – 6:00 PM PT)
At the conclusion of this activity, participants should be able to:
- Integrate validated assessment tools and discuss available biomarker testing to diagnose Alzheimer’s disease early in the course of disease.
- Make timely and appropriate referrals to AD specialists for patients with symptoms of AD or other dementias.
- Assess the safety and efficacy profiles of current and emerging treatment options for Alzheimer’s disease.
This program is CME/AAFP-certified and ABIM MOC-eligible and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by an educational grant from Eisai and is jointly provided by the Potomac Center for Medical Education (PCME) and Rockpointe. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing education, Rockpointe, a leader in educational programming with more than 26 years of experience, strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To register for A New Dawn in Alzheimer’s Disease Management: Recent Advances in Diagnosis and Treatment, click here.